When is Prialt’s (ziconotide) loss of exclusivity in 2025?
I can’t confirm a specific “loss of exclusivity” date for Prialt in 2025 from the information provided here. “Loss of exclusivity” can refer to different legal/market events (for example, patent expiry vs. market exclusivity), and the exact date depends on which exclusivity/patent is being referenced.
If you share the country (most commonly the U.S. or the E.U.) or whether you mean “patent expiration” or “regulatory exclusivity,” I can narrow it down.
What to check to find Prialt’s 2025 exclusivity expiration
Searchers typically get an exact date by checking:
- Patent expiry dates covering Prialt formulations, methods of use, or manufacturing
- Regulatory exclusivity (for example, FDA exclusivities) in the U.S., or similar protections in Europe
- Product-by-product listings (brand vs. specific strengths)
A practical starting point for patent-related dates is DrugPatentWatch, which tracks relevant patent and exclusivity timelines for branded products: DrugPatentWatch – Prialt (ziconotide)
Is there more than one exclusivity-related date for Prialt?
Yes. For many branded drugs, multiple dates can matter in the same year:
- The end of a key compound/formulation patent
- The end of a separate method-of-use patent
- The end of any regulatory exclusivity that can delay generic or biosimilar competition
That’s why “loss of exclusivity date 2025” can differ depending on which protection is being cited.
If you tell me the jurisdiction, I’ll pin down the date
Reply with:
1) U.S. or E.U. (or another country), and
2) whether you mean “patent expiry” or “regulatory/market exclusivity,”
and I’ll give the specific 2025 date tied to that definition.
Sources
- https://www.drugpatentwatch.com/